Literature DB >> 6151046

Amino (hydroxyethoxymethyl) purine: a new well-absorbed prodrug of acyclovir.

P Selby, R L Powles, S Blake, K Stolle, E K Mbidde, T J McElwain, E Hickmott, P D Whiteman.   

Abstract

Acyclovir is an effective treatment for herpes simplex and herpes zoster infections, but it is somewhat limited by low oral absorption. 2-amino-9-[(2hydroxyethoxy)methyl]-9H-purine (BW A515U), a new prodrug of acyclovir, when evaluated in 10 patients with haematological malignancies, was well tolerated, excellently absorbed, and produced high plasma concentrations of acyclovir which were comparable to those with intravenous acyclovir. The plasma concentrations after oral BW A515U were much higher than those after oral acyclovir.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6151046     DOI: 10.1016/s0140-6736(84)91624-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Chemotherapy of herpesvirus infections: present successes and future hopes.

Authors:  S Crowe; J Mills
Journal:  Eur J Clin Microbiol       Date:  1985-10       Impact factor: 3.267

2.  Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution.

Authors:  L D Lewis; A S Fowle; S B Bittiner; A Bye; P E Isaacs
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

Review 3.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

Review 4.  Recognition and treatment of shingles.

Authors:  A F Nikkels; G E Piérard
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

5.  The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.

Authors:  P J Selby; R L Powles; D Easton; T J Perren; K Stolle; B Jameson; A P Fiddian; Y Tryhorn; H Stern
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.